Hsu Po-Kuei, Huang Hsu-Chih, Hsieh Chih-Cheng, Hsu Han-Shui, Wu Yu-Chung, Huang Min-Hsiung, Hsu Wen-Hu
Division of Thoracic Surgery, Department of Surgery, Taipei-Veterans General Hospital National Yang-Ming University, School of Medicine, Taipei, Taiwan.
Ann Thorac Surg. 2007 Dec;84(6):1825-9. doi: 10.1016/j.athoracsur.2007.07.016.
Tumor size is an important prognostic factor in non-small cell lung cancer (NSCLC), but the American Joint Committee on Cancer staging system does not mandate a specific measurement method. Moreover, measuring fresh specimens and formalin-fixed specimens may yield disparate results. Our goal was to evaluate this disparity for stage I NSCLC.
We enrolled 401 patients with stage I NSCLC who underwent surgical interventions and follow-up in our hospital between 1993 and 2002. Tumors invading visceral pleura, involving the main bronchus, or associated with atelectasis or obstructive pneumonitis were excluded. Tumor size was measured immediately after resection by surgeons and after formalin fixation by pathologists. Patients were assigned to one of three groups. Group 1 included 201 patients with tumors of 3 cm or less as indicated by both operation notes and pathology reports. Group 2 included 160 patients with tumors larger than 3 cm by both records. Group 3 included 40 patients with tumors larger than 3 cm according to operation notes but 3 cm or less according to pathology reports. Survival rates were compared.
Mean follow-up was 58 months. Five-year survival was 70.1% in group 1, 49.1% in group 2, and 51.1% in group 3. As expected, there was a significant survival difference between groups 1 and 2 (p < 0.001); however, there was also a difference between groups 1 and 3 (p = 0.006).
Formalin fixation may cause tumor shrinkage and migration from T2 to T1. For accurate tumor staging, size measurements should be performed immediately after resection instead of after formalin fixation. TNM staging should specify how to measure tumor size and the specimen status to be measured.
肿瘤大小是非小细胞肺癌(NSCLC)的一个重要预后因素,但美国癌症联合委员会分期系统并未规定具体的测量方法。此外,测量新鲜标本和福尔马林固定标本可能会产生不同的结果。我们的目标是评估I期NSCLC的这种差异。
我们纳入了1993年至2002年间在我院接受手术干预和随访的401例I期NSCLC患者。排除侵犯脏层胸膜、累及主支气管或伴有肺不张或阻塞性肺炎的肿瘤。肿瘤大小由外科医生在切除后立即测量,并由病理学家在福尔马林固定后测量。患者被分为三组之一。第1组包括201例手术记录和病理报告均显示肿瘤直径为3 cm或更小的患者。第2组包括160例两份记录均显示肿瘤直径大于3 cm的患者。第3组包括40例手术记录显示肿瘤直径大于3 cm但病理报告显示为3 cm或更小的患者。比较生存率。
平均随访58个月。第1组的5年生存率为70.1%,第2组为49.1%,第3组为51.1%。正如预期的那样,第1组和第2组之间存在显著的生存差异(p<0.001);然而,第1组和第3组之间也存在差异(p = 0.006)。
福尔马林固定可能导致肿瘤缩小并从T2期转变为T1期。为了准确进行肿瘤分期,应在切除后立即进行大小测量,而不是在福尔马林固定后。TNM分期应明确如何测量肿瘤大小以及要测量的标本状态。